MADISON, Wis.--(BUSINESS WIRE)--HealthMyne, Inc. today announced the addition of Milton Silva-Craig, J.D., MBA to its board of directors. Silva-Craig, currently CEO of Q-Centrix, brings more than 20 years of executive management expertise in the field of healthcare IT to the board.
Praveen Sinha, CEO at HealthMyne, said: “Prior to Q-Centrix and TransUnion healthcare, Milton was the driver behind the growth of the imaging informatics company, Emageon. His business leadership experience based on a rich history at successful companies will guide us as we prepare for the commercial roll out of our imaging informatics system.”
“I am impressed with HealthMyne’s team and the vision,” said Silva-Craig. “HealthMyne will be an enabling technology to improve outcomes within radiology. Their ability to extract and analyze data from the images as well as the electronic health record will improve the clinician’s view of the whole patient as well as improving the radiology workflow. I look forward to working with the HealthMyne team as they execute their vision of transforming the utility of imaging to benefit all stakeholders.”
About Milton Silva-Craig:
Prior to Q-Centrix, Silva-Craig served as president of TransUnion’s healthcare business unit. His work resulted in an eight-fold increase in business unit growth. At Emageon Inc. (NASDAQ: EMAG), Silva-Craig led the company’s strategic direction and operations. He grew revenues from several hundred thousand dollars to more than $100 million annually, and eventually led Emageon through its IPO. He was also president and CEO of Technology Solutions Company (NASDAQ: TSCC) and held executive positions at GE Medical Systems. Silva-Craig earned a J.D. from the University of Wisconsin-School of Law and obtained his M.B.A. and B.A. from UW Madison as well.
HealthMyne is an imaging informatics company dedicated to transforming patient care by enabling image data mining within the clinical workflow. HealthMyne software will combine imaging and EHR data to provide stakeholders with integrated patient progression timelines as well as analytics for comparing individual patients to specific populations. Academic and industrial researchers can use HealthMyne analytic tools to explore quantitative imaging biomarkers, as well as supporting improved clinical trials of innovative therapies. For more information, visit HealthMyne.com.